| Online-Ressource |
Verfasst von: | Gafita, Andrei [VerfasserIn]  |
| Calais, Jeremie [VerfasserIn]  |
| Grogan, Tristan R [VerfasserIn]  |
| Hadaschik, Boris [VerfasserIn]  |
| Wang, Hui [VerfasserIn]  |
| Weber, Manuel [VerfasserIn]  |
| Sandhu, Shahneen [VerfasserIn]  |
| Kratochwil, Clemens [VerfasserIn]  |
| Esfandiari, Rouzbeh [VerfasserIn]  |
| Tauber, Robert [VerfasserIn]  |
| Zeldin, Anna [VerfasserIn]  |
| Rathke, Hendrik [VerfasserIn]  |
| Armstrong, Wesley R [VerfasserIn]  |
| Robertson, Andrew [VerfasserIn]  |
| Thin, Pan [VerfasserIn]  |
| D'Alessandria, Calogero [VerfasserIn]  |
| Rettig, Matthew B [VerfasserIn]  |
| Delpassand, Ebrahim S [VerfasserIn]  |
| Haberkorn, Uwe [VerfasserIn]  |
| Elashoff, David [VerfasserIn]  |
| Herrmann, Ken [VerfasserIn]  |
| Czernin, Johannes [VerfasserIn]  |
| Hofman, Michael S [VerfasserIn]  |
| Fendler, Wolfgang P [VerfasserIn]  |
| Eiber, Matthias [VerfasserIn]  |
Titel: | Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer |
Titelzusatz: | an international, multicentre, retrospective study |
Verf.angabe: | Andrei Gafita, Jeremie Calais, Tristan R Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R Armstrong, Andrew Robertson, Pan Thin, Calogero D'Alessandria, Matthew B Rettig, Ebrahim S Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Michael S Hofman, Wolfgang P Fendler, Matthias Eiber |
E-Jahr: | 2021 |
Jahr: | July 8, 2021 |
Umfang: | 11 S. |
Teil: | volume:22 |
| year:2021 |
| number:8 |
| month:08 |
| pages:1115-1125 |
| extent:11 |
Fussnoten: | Im Text ist "177" hochgestellt ; Gesehen am 18.10.2021 |
Titel Quelle: | Enthalten in: The lancet <London> / Oncology |
Ort Quelle: | London : The Lancet Publ. Group, 2000 |
Jahr Quelle: | 2021 |
Band/Heft Quelle: | 22(2021), 8 vom: Aug., Seite 1115-1125 |
ISSN Quelle: | 1474-5488 |
Abstract: | Background - Lutetium-177 (177Lu) prostate-specific membrane antigen (177Lu-PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Predictors of outcomes after 177Lu-PSMA to enhance its clinical implementation are yet to be identified. We aimed to develop nomograms to predict outcomes after 177Lu-PSMA in patients with mCRPC. - Methods - In this multicentre, retrospective study, we screened patients with mCRPC who had received 177Lu-PSMA between Dec 10, 2014, and July 19, 2019, as part of the previous phase 2 trials (NCT03042312, ACTRN12615000912583) or compassionate access programmes at six hospitals and academic centres in Germany, the USA, and Australia. Eligible patients had received intravenous 6·0-8·5 GBq 177Lu-PSMA once every 6-8 weeks, for a maximum of four to six cycles, and had available baseline [68Ga]Ga-PSMA-11 PET/CT scan, clinical data, and survival outcomes. Putative predictors included 18 pretherapeutic clinicopathological and [68Ga]Ga-PSMA-11 PET/CT variables. Data were collected locally and centralised. Primary outcomes for the nomograms were overall survival and prostate-specific antigen (PSA)-progression-free survival. Nomograms for each outcome were computed from Cox regression models with LASSO penalty for variable selection. Model performance was measured by examining discrimination (Harrell's C-index), calibration (calibration plots), and utility (patient stratification into low-risk vs high-risk groups). Models were validated internally using bootstrapping and externally by calculating their performance on a validation cohort. - Findings - Between April 23, 2019, and Jan 13, 2020, 414 patients were screened; 270 (65%) of whom were eligible and were divided into development (n=196) and validation (n=74) cohorts. The median duration of follow-up was 21·5 months (IQR 13·3-30·7). Predictors included in the nomograms were time since initial diagnosis of prostate cancer, chemotherapy status, baseline haemoglobin concentration, and [68Ga]Ga-PSMA-11 PET/CT parameters (molecular imaging TNM classification and tumour burden). The C-index of the overall survival model was 0·71 (95% CI 0·69-0·73). Similar C-indices were achieved at internal validation (0·71 [0·69-0·73]) and external validation (0·72 [0·68-0·76]). The C-index of the PSA-progression-free survival model was 0·70 (95% CI 0·68-0·72). Similar C-indices were achieved at internal validation (0·70 [0·68-0·72]) and external validation (0·71 [0·68-0·74]). Both models were adequately calibrated and their predictions correlated with the observed outcome. Compared with high-risk patients, low-risk patients had significantly longer overall survival in the validation cohort (24·9 months [95% CI 16·8-27·3] vs 7·4 months [4·0-10·8]; p<0·0001) and PSA-progression-free survival (6·6 months [6·0-7·1] vs 2·5 months [1·2-3·8]; p=0·022). - Interpretation - These externally validated nomograms that are predictive of outcomes after 177Lu-PSMA in patients with mCRPC might help in clinical trial design and individual clinical decision making, particularly at institutions where 177Lu-PSMA is introduced as a novel therapeutic option. - Funding - Prostate Cancer Foundation. |
DOI: | doi:10.1016/S1470-2045(21)00274-6 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1016/S1470-2045(21)00274-6 |
| Volltext: https://www.sciencedirect.com/science/article/pii/S1470204521002746 |
| DOI: https://doi.org/10.1016/S1470-2045(21)00274-6 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 177433447X |
Verknüpfungen: | → Zeitschrift |
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer / Gafita, Andrei [VerfasserIn]; July 8, 2021 (Online-Ressource)